Skip to menu Skip to content Skip to footer
Dr John Mackintosh
Dr

John Mackintosh

Email: 

Overview

Background

MBBS(Hons), FRACP — Specialist Respiratory and Lung Transplant Physician

Dr John Mackintosh graduated from The University of Queensland in 2011 with honours. He trained in respiratory medicine in Queensland, before completing an interstitial lung disease clinical fellowship at the Royal Brompton Hospital in London — one of the world's leading interstitial lung disease (ILD) referral centres.

He returned to Brisbane in 2019 as a Respiratory & Lung Transplant Physician with the Queensland Lung Transplant Service at The Prince Charles Hospital, and as an academic at The University of Queensland, where he was promoted to Associate Professor in recognition of his clinical and research contribution to ILD. He leads The Prince Charles Hospital's ILD service and his research work centres on ILD, with particular expertise in idiopathic pulmonary fibrosis, familial pulmonary fibrosis and the genetic underpinnings of fibrotic lung disease.

Alongside his clinical practice, he co-chairs the Queensland Statewide ILD Multidisciplinary Meeting and is founder and chair of the Australasian ILD Genetics Multidisciplinary Meeting. Internationally, he was a Co-Lead for the International Society of Heart and Lung Transplantation's first consensus statement on short telomere syndrome and lung transplantation, and is first author of the current Thoracic Society of Australia and New Zealand position statement on the treatment of IPF and progressive pulmonary fibrosis.

Availability

Dr John Mackintosh is:
Not available for supervision

Research impacts

Dr Mackintosh's research centres on interstitial lung disease, with a particular focus on the genetics of pulmonary fibrosis, telomere biology disorders and outcomes after lung transplantation.

Works

Search Professor John Mackintosh’s works on UQ eSpace

84 works between 2012 and 2026

1 - 20 of 84 works

2026

Journal Article

The ASSIST CLAD study: a phase 2 randomized controlled trial of mesenchymal stromal cells for new-onset chronic lung allograft dysfunction

Chambers, Daniel C., Westall, Glen, Darley, David, Musk, Michael, Glanville, Allan R., Malouf, Monique, Holmes-Liew, Chien-Li, Tan, Maxine, Apte, Simon H., Groves, Penelope L., Lutzky, Viviana P., Sturm, Marian J., Lawrence, Sharon, Lawson, Natalee, Singleton, Lisa, Timmins, Sjane, Enever, Debra, Wildermuth, Holly, Daka, Omega, Cooper, Brittany, Winks, Leslie, Haines, Sharon, Zhang, Lai-Ying, Levvey, Bronwyn, Cristiano, Yvonne, Yaw, Meow, Snell, Greg, Trotter, Michael, Carew, Alan ... Hopkins, Peter M.A. (2026). The ASSIST CLAD study: a phase 2 randomized controlled trial of mesenchymal stromal cells for new-onset chronic lung allograft dysfunction. The Journal of Heart and Lung Transplantation, 45 (8), 1310-1318. doi: 10.1016/j.healun.2026.03.032

The ASSIST CLAD study: a phase 2 randomized controlled trial of mesenchymal stromal cells for new-onset chronic lung allograft dysfunction

2026

Journal Article

Palivizumab for donor‐derived RSV infection in an adult bilateral lung transplant recipient: a case report

Meharry, Rosemary, Vale, Cassandra and Mackintosh, John (2026). Palivizumab for donor‐derived RSV infection in an adult bilateral lung transplant recipient: a case report. Respirology Case Reports, 14 (8) e70706, e70706. doi: 10.1002/rcr2.70706

Palivizumab for donor‐derived RSV infection in an adult bilateral lung transplant recipient: a case report

2026

Journal Article

Inhaled treprostinil for idiopathic pulmonary fibrosis

Nathan, Steven D., Smith, Peter, Deng, Chunqin, De Salvo, Maria, Wuyts, Wim, Pavie-Gallegos, Juana, Song, Jin Woo, Kramer, Mordechai R., King, Christopher S., Mackintosh, John A., Chambers, Daniel, Miranda, Georgina Viviana, Breytenbach, Natalie, Peterson, Leigh, Bell, Heidi, Flaherty, Kevin R., Behr, Juergen and Cottin, Vincent (2026). Inhaled treprostinil for idiopathic pulmonary fibrosis. New England Journal of Medicine, 395 (2), 127-137. doi: 10.1056/NEJMoa2512911

Inhaled treprostinil for idiopathic pulmonary fibrosis

2026

Journal Article

Deep-learning algorithm diagnostic support for usual interstitial pneumonia pattern recognition in fibrotic interstitial lung disease

Fermoyle, Caitlin C., Mackintosh, John A., Navaratnam, Vidya, Ellis, Samantha J., Cooper, Wendy A., Goh, Nicole S. L., Moodley, Yuben, Reynolds, Paul N., Zappala, Christopher J., Hopkins, Peter, Glaspole, Ian N., Corte, Tamera J., Walsh, Simon L. F., Accornero, Daniele, Agrawal, Aditya, Akilli, Isil Kibar, Alamoudi, Omer, Alberti, Maria Laura, Aliannejad, Rasoul, Aljahdali, Hamdan, Amanda, Gina, Anconina, Reut, Antuni, Julio Daniel, Aquaro, Giuseppe, Arenas-Jimenez, Juan, Asuquo, Bassey, Au-Yong, Iain, Avdeev, Sergey, Balbi, Maurizio ... Zompatori, Maurizio (2026). Deep-learning algorithm diagnostic support for usual interstitial pneumonia pattern recognition in fibrotic interstitial lung disease. Respirology, 31 (7), 711-720. doi: 10.1002/resp.70246

Deep-learning algorithm diagnostic support for usual interstitial pneumonia pattern recognition in fibrotic interstitial lung disease

2026

Journal Article

Clinical evaluation of long-read sequencing for telomere length assessment in human blood and lung tissues

Lutzky, Viviana P., Rai, Subash K., Tan, Maxine E., Groves, Penny L., Knuckey, Kiara M., Mackintosh, John A., Jones, Mathew J. K., Apte, Simon H. and Chambers, Daniel C. (2026). Clinical Evaluation of Long-Read Sequencing for Telomere Length Assessment in Human Blood and Lung Tissues. Cells, 15 (13) 1165, 1165-1165. doi: 10.3390/cells15131165

Clinical evaluation of long-read sequencing for telomere length assessment in human blood and lung tissues

2026

Journal Article

Idiopathic Pulmonary Fibrosis update, comparing the Australasian Interstitial Lung Disease Registry to the Australian Idiopathic Pulmonary Fibrosis Registry

Chee, Michelle, Khor, Yet Hong, Jackson, Dan, Cooper, Wendy, D’Costa, Jason, de Boer, Sally, Edwards, Adrienne, Ellis, Samantha, Gabbay, Eli, Gallagher, Henry, Glaspole, Ian, Goh, Nicole, Grainge, Christopher, Hopkins, Peter, Keir, Gregory, Kwan, Benjamin, Mackintosh, John, Moodley, Yuben, Moore, Irene, Navaratnam, Vidya, Ong, Chong, Reynolds, Paul, Royals, Karen, Teoh, Alan, Troy, Lauren, Veitch, Elizabeth, Wilsher, Margaret, Wrobel, Jeremy, Zappala, Chris ... on behalf of the AILDR Steering Committee (2026). Idiopathic Pulmonary Fibrosis update, comparing the Australasian Interstitial Lung Disease Registry to the Australian Idiopathic Pulmonary Fibrosis Registry. Internal Medicine Journal, 56 (9) imj.70490, 1518-1527. doi: 10.1111/imj.70490

Idiopathic Pulmonary Fibrosis update, comparing the Australasian Interstitial Lung Disease Registry to the Australian Idiopathic Pulmonary Fibrosis Registry

2026

Conference Publication

International Mapping of Access to Genetic Testing for Interstitial Lung Disease (ILD)

Stanel, S., Lough, G., Emery, H., Adegunsoye, A. O., Aguiar, F. M., Bonella, F., Borie, R., Buendia-Roldan, , Chambers, D., Duckworth, A., Froidure, A., Hunninghake, G. M., Hurley, K. J., Johannson, K. A., Kam, M. L., Kulkarni, T., Mackintosh, J., Molina-Molina, M., Newton, C., Renzoni, E., Wolters, P., Zhang, D., Corte, T. J. and Rivera Ortega, P. (2026). International Mapping of Access to Genetic Testing for Interstitial Lung Disease (ILD). OXFORD: OXFORD UNIV PRESS. doi: 10.1093/ajrccm/aamag162.2493

International Mapping of Access to Genetic Testing for Interstitial Lung Disease (ILD)

2026

Journal Article

Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX): a multicentre, randomised, sham-controlled trial

Holland, Anne E, Hoffman, Mariana, Corte, Tamera J, Chambers, Daniel C, Hepworth, Graham, Ekström, Magnus P, Glaspole, Ian, Goh, Nicole S, Khor, Yet H, Palmer, Andrew J, Barton, Carly, Cox, Ingrid, Dowman, Leona, Einarsson, Jonas, Fuhrmeister, Lisa, Mackintosh, John A, Neglén, Pernilla, Prasad, Jyotika D, Bucciarelli, Jessica, Scherp, Simon, Sköld, Magnus, Smallwood, Natasha, Symons, Karen, Thompson, Michelle and McDonald, Christine F (2026). Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX): a multicentre, randomised, sham-controlled trial. The Lancet Respiratory Medicine, 14 (4), 317-326. doi: 10.1016/S2213-2600(26)00005-6

Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX): a multicentre, randomised, sham-controlled trial

2026

Conference Publication

Palivizumab in donor derived RSV infection in an adult bilateral lung transplant recipient

Meharry, R.S., Vale, C., Winks, L., Vemuri, K., Tse, T., Carew, A., Chambers, D., Trotter, M., Fiene, A., Divithotawela, C., Bell, P., Zhang, L., Hopkins, P. and Mackintosh, J. (2026). Palivizumab in donor derived RSV infection in an adult bilateral lung transplant recipient. 46th Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) (ISHLT2026), Totonto, ON Canada, 22-26 April 2026. Philadelphia, PA United States: Elsevier. doi: 10.1016/j.healun.2026.02.782

Palivizumab in donor derived RSV infection in an adult bilateral lung transplant recipient

2026

Journal Article

Corrigendum to “Elastin distribution in lung tumours, including non-small cell lung Carcinoma”

Duhig, Edwina, Walsh, Michael, Lal, Sameeta, van Zwieten, Anthony, Broomfield, Amy, Stephens, Edward, Jaffrey, Daniel, Goldsworthy, Anita, Godbolt, David, Davidson, Morgan, Mackintosh, John, Hopkins, Peter, Chambers, Daniel, Bowman, Rayleen, Fong, Kwun and Yang, Ian (2026). Corrigendum to “Elastin distribution in lung tumours, including non-small cell lung Carcinoma”[Pathol 58 (supplement 1) S11]. Pathology, 58 (5), S11-642. doi: 10.1016/j.pathol.2026.03.003

Corrigendum to “Elastin distribution in lung tumours, including non-small cell lung Carcinoma”

2026

Conference Publication

The Australasian Interstitial Lung Disease Registry (AILDR): demographics, disease characteristics, and transplant-free survival insights from a bi-national cohort

Fraser, A., Zhao, C., Glaspole, , Glenn, L., Goh, N., Mackintosh, J., Symons, K., Wilsher, M., Chambers, D., D'Costa, J., de Boer, S., Edwards, A., Gabbay, E., Gallagher, H., Grainge, C., Keir, G., Khor, Y., Kwan, B., Lim, K. P., Moodley, Y., Moore, , Navaratnam, , Ong, C., Polasek, J., Reynolds, P., Teoh, A., Thien, F., Troy, L., Veitch, E. ... Corte, T. (2026). THE AUSTRALASIAN INTERSTITIAL LUNG DISEASE REGISTRY (AILDR): DEMOGRAPHICS, DISEASE CHARACTERISTICS, AND TRANSPLANT-FREE SURVIVAL INSIGHTS FROM A BI-NATIONAL COHORT. HOBOKEN: WILEY.

The Australasian Interstitial Lung Disease Registry (AILDR): demographics, disease characteristics, and transplant-free survival insights from a bi-national cohort

2026

Conference Publication

The relationship between anti-ro antibodies, phenotype and outcomes in the Australasian Interstitial Lung Disease Registry

Watson, Stella, Hansen, Dylan, Glaspole, Ian, Glenn, Laura, Goh, Nicole, Mackintosh, John, Symons, Karen, Wilsher, Margaret, Wrobel, Jeremy, Chambers, Daniel, D'costa, Jason, De Boer, Sally, Edwards, Adrienne, Gabbay, Eli, Gallagher, Henry, Grainge, Christopher, Keir, Gregory, Kwan, Ben, Lim, K. P., Moodley, Yuben, Moore, Irene, Navaratnam, Vidya, Ong, Chong, Polasek, Jonathon, Reynolds, Paul, Teoh, Alan, Thien, Frank, Troy, Lauren, Veitch, Elizabeth ... Parker, Matthew J. S. (2026). THE RELATIONSHIP BETWEEN ANTI-RO ANTIBODIES, PHENOTYPE AND OUTCOMES IN THE AUSTRALASIAN INTERSTITIAL LUNG DISEASE REGISTRY. HOBOKEN: WILEY.

The relationship between anti-ro antibodies, phenotype and outcomes in the Australasian Interstitial Lung Disease Registry

2026

Journal Article

Relationship between pulmonary function and six-minute walk-test performance in ILD

Reeves, J., Roberston, L., Rogers, K., Zhao, C., Glaspole, , Glenn, L., Goh, N., Mackintosh, J., Symons, K., Wilsher, M., Chambers, D., D'costa, J., De Boer, S., Edwards, A., Gabbay, E., Gallagher, H., Grainge, C., Keir, G., Khor, Y., Kwan, B., Lim, Kp, Moodley, Y., Moore, , Navaratnam, , Ong, C., Polasek, J., Reynolds, P., Teoh, A., Thien, F. ... Corte, T. (2026). RELATIONSHIP BETWEEN PULMONARY FUNCTION AND SIX-MINUTE WALK-TEST PERFORMANCE IN ILD. HOBOKEN: WILEY.

Relationship between pulmonary function and six-minute walk-test performance in ILD

2026

Conference Publication

Impact of the size of FVC decline on lung transplant-free survival among the Australasian Interstitial Lung Disease Registry (AILDR) patients

Li, Andrew, Stewart, Iain, Higginson, Emily, Buck, Evan, Teoh, Alan, Glenn, Laura, Troy, Lauren, Glaspole, Ian, Symons, Karen, Wilsher, Margaret, De Boer, Sally, Wrobel, Jeremy, Moodley, Yuben, Thien, Francis, Gallagher, Henry, Chambers, Daniel, Mackintosh, John, Goh, Nicole, Khor, Yet, Edwards, Adrienne, Grainge, Christopher, Kwan, Benjamin, Keir, Gregory, Ong, Chong, Reynolds, Paul, Veitch, Elizabeth, Gabbay, Eli, Pin, Lim Kuan, Polasek, Jonathon ... Corte, Tamera (2026). IMPACT OF THE SIZE OF FVC DECLINE ON LUNG TRANSPLANT-FREE SURVIVAL AMONG THE AUSTRALASIAN INTERSTITIAL LUNG DISEASE REGISTRY (AILDR) PATIENTS. HOBOKEN: WILEY.

Impact of the size of FVC decline on lung transplant-free survival among the Australasian Interstitial Lung Disease Registry (AILDR) patients

2026

Conference Publication

Immunohistochemical expression within lung disease including carcinoma, with reference to cell lineage, the tumour microenvironment and elastin related proteins

Duhig, Edwina, van Zwieten, Anthony, Broomfield, Amy, Walsh, Michael, Lal, Sameeta, Godbolt, David, Davidson, Morgan, Mackintosh, John, Hopkins, Peter, Chambers, Daniel, Bowman, Rayleen, Fong, Kwun and Yang, Ian (2026). Immunohistochemical expression within lung disease including carcinoma, with reference to cell lineage, the tumour microenvironment and elastin related proteins. Pathology Update 2026, Sydney, NSW Australia, 6-8 March. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.pathol.2026.01.049

Immunohistochemical expression within lung disease including carcinoma, with reference to cell lineage, the tumour microenvironment and elastin related proteins

2026

Journal Article

Likelihood of usual interstitial pneumonia: a novel approach to prognosis for pulmonary fibrosis

Mackintosh, John A., Walsh, Simon L. F., Silva, Mario, Calandriello, Lucio, Humphries, Stephen M., Lynch, David A., Jo, Helen E., Glaspole, Ian, Grainge, Christopher, Goh, Nicole, Hopkins, Peter M. A., Moodley, Yuben, Reynolds, Paul N., Zappala, Christopher, Keir, Gregory, Cooper, Wendy A., Mahar, Annabelle M., Ellis, Samantha, Wells, Athol U. and Corte, Tamera J. (2026). Likelihood of Usual Interstitial Pneumonia: A Novel Approach to Prognosis for Pulmonary Fibrosis. Respirology, 31 (5) PMID 9616368, 521-529. doi: 10.1002/resp.70196

Likelihood of usual interstitial pneumonia: a novel approach to prognosis for pulmonary fibrosis

2026

Journal Article

Clearing the haze around familial interstitial lung abnormalities

Bajwa, Ramey and Mackintosh, John (2026). Clearing the haze around familial interstitial lung abnormalities. Thorax. doi: 10.1136/thorax-2026-225326

Clearing the haze around familial interstitial lung abnormalities

2026

Journal Article

Primed to React: Neutrophil-To-Lymphocyte Ratio to Predict Severe Checkpoint Inhibitor Pneumonitis

Mackintosh, John A. (2026). Primed to React: Neutrophil-To-Lymphocyte Ratio to Predict Severe Checkpoint Inhibitor Pneumonitis. Respirology, 31 (9), 864-865. doi: 10.1002/resp.70294

Primed to React: Neutrophil-To-Lymphocyte Ratio to Predict Severe Checkpoint Inhibitor Pneumonitis

2026

Journal Article

Do we need to prioritise interstitial lung disease clinical diagnoses? A comment on the 2025 interstitial pneumonia statement

Fraser, Ashley, Tsai, Ling-Ling, Fermoyle, Caitlin C., Mortimer, Nathan, Troy, Lauren, Mackintosh, John, Chambers, Daniel C., Goh, Nicole, Milne, David, Wrobel, Jeremy, Wilsher, Margaret, de Boer, Sally, Parker, Matthew J S, Webster, Susanne, Baker, Amy, Hyde, Tania, Alison, Jennifer and Corte, Tamera J. (2026). Do we need to prioritise interstitial lung disease clinical diagnoses? A comment on the 2025 interstitial pneumonia statement. The European respiratory journal, 67 (1) 2501987, 2501987. doi: 10.1183/13993003.01987-2025

Do we need to prioritise interstitial lung disease clinical diagnoses? A comment on the 2025 interstitial pneumonia statement

2025

Journal Article

A randomised clinical trial of a digital self-management package for people with interstitial lung disease: the REBUILD-SM protocol

Barton, Carly, Hoffman, Mariana, Cox, Narelle S., Glenn, Laura M., Lee, Joanna Y. T., Cox, Ingrid, Goh, Nicole S. L., Troy, Lauren K., Mackintosh, John, Chambers, Daniel C., Glaspole, Ian N., Gebski, Val, Keech, Anthony, Palmer, Andrew, Laranjo, Liliana, Knibbs, Luke D., Moodley, Yuben, Brooke, Mark, Holland, Anne E. and Corte, Tamera J. (2025). A randomised clinical trial of a digital self-management package for people with interstitial lung disease: the REBUILD-SM protocol. Respiratory Research, 27 (1) 14. doi: 10.1186/s12931-025-03442-z

A randomised clinical trial of a digital self-management package for people with interstitial lung disease: the REBUILD-SM protocol

Funding

Current funding

  • 2023 - 2028
    Treatable Traits in Interstitial Lung Disease (TTRILD) Study: The New Frontier (MRFF Preventive and Public Health Research Initiative grant administered by The University of Western Australia)
    University of Western Australia
    Open grant

Past funding

  • 2020 - 2025
    The TELO-SCOPE study: Attenuating Telomere Attrition with Danazol. Is there Scope to Dramatically Improve Health Outcomes for Adults and Children with Pulmonary Fibrosis?
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant

Media

Enquiries

For media enquiries about Dr John Mackintosh's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au